Mankind Pharma IPO subscribed 32% so far on Day 2. Check GMP and other details.

Mankind Pharma's initial public offering (IPO), which will close on January 19, has been subscribed by 32% on Day 2 with non-institutional investors and qualified institutional buyers subscribing the most. Retail investors' quota had 16% bids. Nine brokerages recommended the issue, saying that growth opportunities outweigh concerns about high valuation. Mankind Pharma has raised around Rs 1,297 crore by allocating 1.2 crore equity shares to 77 anchor investors, which include Goldman Sachs, Canada Pension Plan and Government of Singapore. At the higher end of the price band, Mankind Pharma valued at 30x FY22 EPS.

Mankind Pharma IPO subscribed 32% so far on Day 2. Check GMP and other details.
Mankind Pharma's initial public offering (IPO), which will close on January 19, has been subscribed by 32% on Day 2 with non-institutional investors and qualified institutional buyers subscribing the most. Retail investors' quota had 16% bids. Nine brokerages recommended the issue, saying that growth opportunities outweigh concerns about high valuation. Mankind Pharma has raised around Rs 1,297 crore by allocating 1.2 crore equity shares to 77 anchor investors, which include Goldman Sachs, Canada Pension Plan and Government of Singapore. At the higher end of the price band, Mankind Pharma valued at 30x FY22 EPS.